JeffreySosmanMD

Hematology • Chicago, IL

Professor of Medicine, Vanderbilt University

Join to view full profile

Dr. Sosman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sosman's full profile

Already have an account?

Office
675 N Saint Clair St
Ste 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1989
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1985 - 1986
University of ChicagoResidency, Pathology-Anatomic and Clinical, 1982 - 1985
University of ChicagoInternship, Internal Medicine, 1981 - 1982
Albert Einstein College of MedicineClass of 1981

Certifications & Licensure

IL State Medical License 1981 - 2026
TN State Medical License 2001 - 2016
WI State Medical License 1985 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
American Board of Pathology Anatomic Pathology

Clinical Trials

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

119 citations
Non-viral precision T cell receptor replacement for personalized cell therapy.
Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan
Nature. 2023-03-01
77 citations
A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors
Igor Puzanov, Colin R Lindsay, Laura W. Goff, Jeffrey A. Sosman, Jill Gilbert
Clinical Cancer Research. 2015-02-15
10985 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, R. W. Weber, Jeffrey A. Sosman
The New England Journal of Medicine. 2010-08-18

Press Mentions

Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024